On March 8, 2022 OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, reported that preclinical data demonstrating synergy between OKI-179, the Company’s oral Class I histone deacetylase (HDAC) inhibitor, and the MEK inhibitor, binimetinib, in NRAS melanoma models has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, OnKure, MAR 8, 2022, View Source;utm_medium=rss&utm_campaign=onkure-therapeutics-to-present-late-breaking-preclinical-data-on-oki-179-at-the-aacr-annual-meeting-2022 [SID1234609663]). The meeting will be held in New Orleans, Louisiana from April 8, 2022 to April 13, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Late-Breaker Poster Presentation:

Title: The class I selective, oral HDAC inhibitor OKI-179 increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma

Session: Late-Breaking Research: Experimental and Molecular Therapeutics 2

Abstract ID: LB204

Date/Time: Wednesday, April 13, 2022; 9:00 a.m. – 12:30 p.m. CT

The e-poster and abstract will be available starting Friday, April 8, 2022 at 1 p.m. ET on the AACR (Free AACR Whitepaper) Annual Meeting 2022 website(opens in a new tab).